GSTZ1 genotypes correlate with dichloroacetate pharmacokinetics and chronic side effects in multiple myeloma patients in a pilot phase 2 clinical trial

Dichloroacetate (DCA) is an investigational drug targeting the glycolytic hallmark of cancer by inhibiting pyruvate dehydrogenase kinases (PDK). It is metabolized by GSTZ1, which has common polymorphisms altering enzyme or promoter activity. GSTZ1 is also irreversibly inactivated by DCA. In the firs...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Dan Dan, Bennett, Samuel K., Coupland, Lucy A., Forwood, Kathryn, Lwin, Yadanar, Pooryousef, Niloofar, Tea, Illa, Truong, Thy T., Neeman, Teresa, Crispin, Philip, D’Rozario, James, Blackburn, Anneke C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783648/
https://www.ncbi.nlm.nih.gov/pubmed/31624634
http://dx.doi.org/10.1002/prp2.526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783648/
https://www.ncbi.nlm.nih.gov/pubmed/31624634
http://dx.doi.org/10.1002/prp2.526

Ejemplares similares